US4800191A
Expired / Lapsed
US
⏱️ 0.0 years remaining
LHRH antagonists
Assignee: Tulane University
•
Filing: 1987-07-17
•
Granted: 1989-01-24
•
Expires: 2007-07-17
Abstract
Abstract The present invention deals with LHRH antagonists which possess improved water solubility and while having the high antagonist potency of the basic peptides, are free of the edematogenic effects. These compounds are highly potent in inhibiting the release of gonadotropins from the pituitary gland in mammals, including humans. The compounds of this invention are represented by the formula X-R1-R2-R3-Ser-Tyr-R6-Leu-Arg-Pro-R10-NH2 wherein X is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, R1 is D- or L-Pro, D- or L- DELTA 3-Pro, D-Phe, D-Phe(4-H1), D-Ser, D-Thr, D-Ala, D-Nal (1) or D-Nal (2), R2 is D-Phe or D-Phe(4-H1) R3 is D-Trp, D-Phe, D-Pal, D-Nal(1) or D-Nal (2), R6 is D-Cit, D-Hci, D-Cit(Q) or D-Hci(Q) and R10 is Gly or D-Ala where Q is lower alkyl of 1-3 carbon atoms and H1 is fluoro, chloro or bromo, and the pharmaceutically acceptable acid addition salts thereof and methods of use pertaining to these compounds.
Inventors
- 👤 Andrew V. Schally
- 👤 Sandor Bajusz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 10:31
CPC Classifications
C; C07; C07K; C07K7/00; C07K7/04; C07K7/23; A; A61; A61P; A61P15/00; A61P15/18; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/11; Y10S930/12; Y10S930/13
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
116 words
A peptide selected from the group of peptides having the formula: X-R.sup.1 -R.sup.2 -R.sup.3 -Ser-Tyr-R.sup.6 -Leu-Arg-Pro-R.sup.10 -NH.sub.2 wherein X is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, R 1 is D- or L-Pro, D- or L-Δ 3 -Pro, D-Phe, D-Phe(4-H1), D-Ser, D-Thr, D-Ala, D-Nal(1) or D-Nal (2), R 2 is D-Phe or D-Phe(4-H1), R 3 is D-Trp, D-Phe, D-Pal, D-Nal(1) or D-Nal (2), R 6 is D-Cit, D-Hci, D-Cit(Q) or D-Hci(Q) and R 10 is Gly or D-Ala, where Q2 is lower alkyl of 1-3 carbon atoms and H1 is fluoro, chloro or bromo, and the pharmaceutically acceptable acid addition salts thereof.
Claim 2
Dependent Claim
116 words
A peptide selected from the group of peptides having the formula: X-R.sup.1 -R.sup.2 -R.sup.3 -Ser-Tyr-R.sup.6 -Leu-Arg-Pro-R.sup.10 -NH.sub.2 wherein X is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, R 1 is D- or L-Pro, D- or L-Δ 3 -Pro, D-Phe, D-Phe(4-H1), D-Ser, D-Thr, D-Ala, D-Nal(1) or D-Nal (2), R 2 is D-Phe or D-Phe(4-H1), R 3 is D-Trp, D-Phe, D-Pal, D-Nal(1) or D-Nal (2), R 6 is D-Cit, D-Hci, D-Cit(Q) or D-Hci(Q) and R 10 is Gly or D-Ala, where Q2 is lower alkyl of 1-3 carbon atoms and H1 is fluoro, chloro or bromo, and the pharmaceutically acceptable acid addition salts thereof.
Claim 3
Dependent Claim
27 words
A peptide of claim 1 wherein R 1 is D- or L-Pro, D-Phe, D-Phe(4-Cl), D-Nal (2), R 2 is D-Phe(4-F) or D-Phe(4-Cl), and R 3 is D-Trp.
Claim 4
Dependent Claim
195 words
A peptide selected from the group of peptides having the formula: X-R.sup.1 -R.sup.2 -R.sup.3 -Ser(X.sup.4)-Tyr(X.sup.5)-R.sup.*6 (X.sup.6)-Leu-Arg(X.sup.8)-Pro-R.sup.10 -NH-X.sup.10 wherein X is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, t-Boc or hydrogen, X 4 is hydrogen or a protecting group for the Ser hydroxyl group, X 5 is hydrogen or a protecting group for the Tyr phenolic hydroxyl group, X 6 is hydrogen or a protecting group for the Lys or Orn side chain amino group, X 8 is hydrogen or a protecting group for the Arg guanidino group, X 10 is hydrogen or a resin support containing benzhydryl or methylbenzhydryl groups, R 1 is D- or L-Pro, D- or LΔ 3 -Pro, D-Phe, D-Phe(4-H1), D-Ser, D-Thr, D-Ala, D-Nal(1) or D-Nal (2), R 2 is D-Phe or D-Phe(4-H1), R 3 is D-Trp, D-Phe, D-Pal, D-Nal(1) or D-Nal (2), R 6 is D-Lys or D-Orn and R 10 is Gly or D-Ala, where H1 is fluoro, chloro or bromo, provided that where X is t-Boc or hydrogen, X 4 , X 5 , X 6 , and X 8 must be other than hydrogen.
Claim 5
Dependent Claim
195 words
A peptide selected from the group of peptides having the formula: X-R.sup.1 -R.sup.2 -R.sup.3 -Ser(X.sup.4)-Tyr(X.sup.5)-R.sup.*6 (X.sup.6)-Leu-Arg(X.sup.8)-Pro-R.sup.10 -NH-X.sup.10 wherein X is an acyl group derived from straight or branched chain aliphatic or alicyclic carboxylic acids having from 1 to 7 carbon atoms, t-Boc or hydrogen, X 4 is hydrogen or a protecting group for the Ser hydroxyl group, X 5 is hydrogen or a protecting group for the Tyr phenolic hydroxyl group, X 6 is hydrogen or a protecting group for the Lys or Orn side chain amino group, X 8 is hydrogen or a protecting group for the Arg guanidino group, X 10 is hydrogen or a resin support containing benzhydryl or methylbenzhydryl groups, R 1 is D- or L-Pro, D- or LΔ 3 -Pro, D-Phe, D-Phe(4-H1), D-Ser, D-Thr, D-Ala, D-Nal(1) or D-Nal (2), R 2 is D-Phe or D-Phe(4-H1), R 3 is D-Trp, D-Phe, D-Pal, D-Nal(1) or D-Nal (2), R 6 is D-Lys or D-Orn and R 10 is Gly or D-Ala, where H1 is fluoro, chloro or bromo, provided that where X is t-Boc or hydrogen, X 4 , X 5 , X 6 , and X 8 must be other than hydrogen.
Claim 6
Dependent Claim
37 words
A Peptide of claim 3 wherein X 4 is hydrogen or 2,6-dichloro-benzyl, X 5 is hydrogen or Z(2-Br) or 2,6-dichlorobenzyl, X 6 is hydrogen or Z(2-Cl) and X 8 is hydrogen, nitro, Tos, methyl-(t-butylbenzyl)sulfonyl or 4-methoxy-2,3,6-trimethyl benzylsulfonyl.
Claim 7
Dependent Claim
28 words
A Peptide of claim 4 wherein X 4 and X 5 are hydrogen or benzyl, X 6 is hydrogen or Z(2Cl), and X 8 is hydrogen or Tos.
Claim 8
Dependent Claim
9 words
A peptide of claim 2 wherein X is acetyl.
Claim 9
Dependent Claim
10 words
A peptide of claim 6 wherein R 1 is Pro.
Claim 10
Dependent Claim
10 words
A peptide of claim 6 wherein R 1 is D-Nal(2).
Claim 11
Dependent Claim
10 words
A peptide of claim 6 wherein R 1 is D-Phe(4-Cl).
Claim 12
Dependent Claim
10 words
A peptide of claim 6 wherein R 1 is D-Phe.
Claim 13
Dependent Claim
12 words
A peptide of claim 7 wherein R 6 is D-Cit or D-Cit(Et).
Claim 14
Dependent Claim
12 words
A peptide of claim 7 wherein R 6 is D-Hci or D-Hci(Et).
Claim 15
Dependent Claim
12 words
A peptide of claim 8 wherein R 6 is D-Hci or D-Cit.
Claim 16
Dependent Claim
12 words
A peptide of claim 9 wherein R 6 is D-Hci or D-Cit.
Claim 17
Dependent Claim
12 words
A peptide of claim 10 wherein R 6 is D-Cit or D-Cit(Et).
Claim 18
Dependent Claim
12 words
A peptide of claim 10 wherein R 6 is D-Hci or D-Hci(Et).
Claim 19
Dependent Claim
31 words
A pharmaceutical composition for reducing the physiological availability of pituitary gonadotropins in a mammal which comprises a reductively effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
Claim 20
Dependent Claim
31 words
A method of reducing the physiological availability of pituitary gonadotropins in mammals in need of such reduction which comprises administering thereto a reductively effective amount of a compound of claim 1.
Claim 21
Dependent Claim
18 words
A method of claim 18 wherein the amount is between 0.1 and 2.5 mg/kg body weight per day.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-01-24 | 1992-07-25 | 1993-01-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-01-24 | 1996-07-25 | 1997-01-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-01-24 | 2000-07-25 | 2001-01-24 | $7700.00 | Window Closed / Lapsed |